Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA
An Open-label, Single-arm, Active-treatment, Efficacy and Safety Study of Canakinumab (ACZ885) Administered for at Least 48 Weeks in Japanese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
Sponsor: Novartis Pharmaceuticals
A PHASE3 clinical study on Systemic Juvenile Idiopathic Arthritis, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 10 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2019 — Oct 2019 [monthly]
Completed PHASE3
-
Oct 2018 — Jan 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .